Lunai Bioworks Inc. develops AI-powered drug discovery, diagnostics, and biodefense platforms through proprietary biomedical datasets, machine learning, and its wholly owned subsidiary BioSymetrics.
Recurring company news covers BioSymetrics programs in precision neurology, Parkinson's disease biomarker discovery, alcohol use disorder therapeutics, and AI-enabled screening models using zebrafish and neurotoxicity datasets. Updates also include the company's transformer-based safety intelligence for generative biology, biodefense and countermeasure initiatives, European restructuring, strategic collaborations, corporate name and ticker changes, Nasdaq compliance actions, and reverse stock split activity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.